Mesenchymal stem cells in dogs with demyelinating leukoencephalitis as an experimental model of multiple sclerosis

Background Multiple sclerosis is an inflammatory, neurodegenerative disease of the central nervous system for which therapeutic mesenchymal stem cell transplantation is under study. Published experience of culture-expanding multiple sclerosis patients’ mesenchymal stem cells for clinical trials is limited. Objective To determine the feasibility of culture-expanding multiple sclerosis patients’ mesenchymal stem cells for clinical use. Methods In a phase I trial, autologous, bone marrow-derived mesenchymal stem cells were isolated from 25 trial participants with multiple sclerosis and eight matched controls, and culture-expanded to a target single dose of 1–2 × 106 cells/kg. Viability, cell product identity and sterility were assessed prior to infusion. Cytogenetic stability was assessed by single nucleotide polymorphism analysis of mesenchymal stem cells from 18 multiple sclerosis patients and five controls. Results One patient failed screening. Mesenchymal stem cell culture expansion was successful for 24 of 25 multiple sclerosis patients and six of eight controls. The target dose was achieved in 16–62 days, requiring two to three cell passages. Growth rate and culture success did not correlate with demographic or multiple sclerosis disease characteristics. Cytogenetic studies identified changes on one chromosome of one control (4.3%) after extended time in culture. Conclusion Culture expansion of mesenchymal stem cells from multiple sclerosis patients as donors is feasible. However, culture time should be minimized for cell products designated for therapeutic administration.

Download Full-text

The potentials of umbilical cord-derived mesenchymal stem cells in the treatment of multiple sclerosis

Reviews in the Neurosciences ◽

10.1515/revneuro-2018-0057 ◽

2019 ◽

Vol 30 (8) ◽

pp. 857-868 ◽

Cited By ~ 1

Author(s):

Ahmad Mehdipour ◽

Ayyub Ebrahimi ◽

Mohammad-Reza Shiri-Shahsavar ◽

Jafar Soleimani-Rad ◽

Leila Roshangar ◽

...

Keyword(s):

Multiple Sclerosis ◽

Stem Cells ◽

Mesenchymal Stem Cells ◽

Cell Therapy ◽

Umbilical Cord ◽

Treatment Option ◽

Adult Mesenchymal Stem Cells ◽

The Central Nervous System ◽

Promising Treatment ◽

Different Sources

AbstractStem cell therapy has indicated a promising treatment capacity for tissue regeneration. Multiple sclerosis is an autoimmune-based chronic disease, in which the myelin sheath of the central nervous system is destructed. Scientists have not discovered any cure for multiple sclerosis, and most of the treatments are rather palliative. The pursuit of a versatile treatment option, therefore, seems essential. The immunoregulatory and non-chronic rejection characteristics of mesenchymal stem cells, as well as their homing properties, recommend them as a prospective treatment option for multiple sclerosis. Different sources of mesenchymal stem cells have distinct characteristics and functional properties; in this regard, choosing the most suitable cell therapy approach seems to be challenging. In this review, we will discuss umbilical cord/blood-derived mesenchymal stem cells, their identified exclusive properties compared to another adult mesenchymal stem cells, and the expectations of their potential roles in the treatment of multiple sclerosis.

Download Full-text